术中PSMA PET/CT评估手术切缘及其在前列腺癌根治术中的预后价值
本研究纳入7例高危前列腺癌患者,术前注射[18F]PSMA-1007,前列腺切除后行离体PET/CT并使用4种半自动分割方法评估功能肿瘤体积,与组织病理学对比切缘和体积。采用迭代阈值法时切缘检测灵敏度83%、特异度100%、阳性预测值100%、阴性预测值92%。1例患者术后1年内出现生化复发,1例接受辅助放疗,其余5例随访无生化复发证据。
要点
- 迭代阈值法离体PET/CT切缘检测灵敏度83%、特异度100%、阳性预测值100%、阴性预测值92%。
- 基于体模推导的最小可分割活度浓度约2 kBq/mL,作者提出术前注射[18F]PSMA-1007活度至少1.9 MBq/kg、术中注射至少0.4 MBq/kg。
- 术中离体PET/CT是术中对切缘评估有前景的方法,作者指出需前瞻性试验进一步研究其价值。
核心结论
- 术中离体PET/CT是术中对切缘评估有前景的方法。
- 作者指出需前瞻性试验进一步研究标本PET/CT引导放射引导手术在高危前列腺癌中的价值。
研究设计与样本
- 研究纳入7例高危前列腺癌患者,术前接受[18F]PSMA-1007,根治性前列腺切除后行AURA 10 PET/CT系统离体成像。
- 使用4种半自动分割方法分割功能肿瘤体积,并将切缘和体积与组织病理学对比。
- 另进行支持性体模研究以评估低放射性药物活度下的分割准确性。
主要发现
- 临床上在术中PET/CT中分析18个病灶,采用迭代阈值法时切缘检测灵敏度83%、特异度100%、阳性预测值100%、阴性预测值92%。
- 1例患者在前列腺特异性抗原随访1年内观察到生化复发,1例患者接受辅助放疗。
- 其余5例患者仍在前列腺特异性抗原随访中,无生化复发证据。
- 基于体模推导的最小可分割活度浓度约2 kBq/mL,作者提出术前注射[18F]PSMA-1007活度至少1.9 MBq/kg、术中注射至少0.4 MBq/kg。
关键数值与推荐
- 采用迭代阈值法时,离体PET/CT切缘检测灵敏度83%、特异度100%、阳性预测值100%、阴性预测值92%。
- 体模推导的最小可分割活度浓度约2 kBq/mL。
- 作者提出术前注射[18F]PSMA-1007活度至少1.9 MBq/kg,术中注射至少0.4 MBq/kg。
临床怎么用
- 原文未据此给出推荐。
局限性
- 作者指出需前瞻性试验进一步研究标本PET/CT引导放射引导手术在高危前列腺癌中的价值。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Detection of positive resection margins in surgical procedures of high-risk prostate cancer is key for minimizing the risk of recurrence. This study aimed at evaluating the accuracy of functional tumor-volume segmentation in intraoperative ex vivo PET/CT for margin assessment in prostate cancer patients undergoing radical prostatectomy. Methods: Seven high-risk prostate cancer patients received [18F]PSMA-1007 before radical prostatectomy. After removal of the prostate gland, ex vivo imaging on the AURA 10 PET/CT system was performed, and functional tumor volume was segmented using 4 semiautomatic segmentation methods. Resection margins and volumes were compared with histopathology. Additionally, a supportive phantom study was conducted to assess segmentation accuracy at low radiopharmaceutical activity. Results: Clinically, 18 lesions were analyzed in intraoperative PET/CT. Sensitivity, specificity, and positive and negative predictive values of margin detection were 83%, 100%, 100%, and 92%, respectively, using an iterative thresholding method. In 1 patient, a biochemical recurrence was observed within 1 y of prostate-specific antigen follow-up, and 1 patient underwent adjuvant radiotherapy. The remaining 5 patients were still undergoing prostate-specific antigen follow-up with no evidence of biochemical recurrence. On the basis of a phantom-deduced minimal segmentable activity concentration of approximately 2 kBq/mL, we propose an administered [18F]PSMA-1007 activity of at least 1.9 and 0.4 MBq/kg for preoperative and intraoperative injections, respectively. Conclusion: Intraoperative ex vivo PET/CT is a promising modality for intraoperative margin assessment. Prospective trials are needed to further investigate the value of specimen PET/CT-based radioguided surgery in high-risk prostate cancer.
引用
- Moraitis A, Kahl T, Kandziora J, et al. Evaluation of Surgical Margins with Intraoperative PSMA PET/CT and Their Prognostic Value in Radical Prostatectomy. J Nucl Med. 2025. PMID: 39915125. doi:10.2967/jnumed.124.268719
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。